India Welcomes New Hope for Psoriasis and Psoriatic Arthritis Patients with Eli Lilly’s Copellor® Launch
Eli Lilly, one of the world’s leading pharmaceutical companies, has launched Copellor® (Ixekizumab) in India to bring relief to adults with moderate-to-severe plaque psoriasis and active psoriatic arthritis. Copellor® is a humanized IgG4 monoclonal antibody that specifically targets the IL-17A protein, which plays a key role in causing inflammation in psoriasis. The drug is available in a single-dose prefilled autoinjector of 80mg/ml strength.
The launch of Copellor® in India is particularly significant because psoriasis is a chronic autoimmune disease that affects up to 3% of the Indian population. According to a recent study, the prevalence of psoriasis in India is estimated to be between 0.44% and 2.8%, making it a major health concern. Furthermore, psoriasis often leads to psoriatic arthritis, which affects up to 30% of psoriasis patients. Copellor® provides a new treatment option for patients who have not responded to traditional therapies.
Vineet Gupta, Managing Director of Eli Lilly and Company – India & India Subcontinent, said: “The launch of Copellor® in India is a significant milestone in our mission to bring innovative medicines to the country. We are proud to offer a new treatment option for patients with moderate-to-severe plaque psoriasis and active psoriatic arthritis, which are both debilitating conditions. Copellor® is a testament to our commitment to improving the health and quality of life of people living with chronic diseases.”
Eli Lilly’s Copellor® launch in India marks a significant step forward in the treatment of psoriasis and psoriatic arthritis. Copellor® provides a new option for patients who have not found relief from traditional therapies and offers hope to millions of people living with these chronic conditions. Eli Lilly’s dedication to bringing innovative medicines to India is commendable, and the launch of Copellor® reaffirms their commitment to meeting the healthcare needs of people around the world.